Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection

PLoS One. 2013 Jun 18;8(6):e65950. doi: 10.1371/journal.pone.0065950. Print 2013.

Abstract

HIV-1 subtype C (C-HIV) is responsible for most HIV-1 cases worldwide. Although the pathogenesis of C-HIV is thought to predominantly involve CCR5-restricted (R5) strains, we do not have a firm understanding of how frequently CXCR4-using (X4 and R5X4) variants emerge in subjects with progressive C-HIV infection. Nor do we completely understand the molecular determinants of coreceptor switching by C-HIV variants. Here, we characterized a panel of HIV-1 envelope glycoproteins (Envs) (n = 300) cloned sequentially from plasma of 21 antiretroviral therapy (ART)-naïve subjects who experienced progression from chronic to advanced stages of C-HIV infection, and show that CXCR4-using C-HIV variants emerged in only one individual. Mutagenesis studies and structural models suggest that the evolution of R5 to X4 variants in this subject principally involved acquisition of an "Ile-Gly" insertion in the gp120 V3 loop and replacement of the V3 "Gly-Pro-Gly" crown with a "Gly-Arg-Gly" motif, but that the accumulation of additional gp120 "scaffold" mutations was required for these V3 loop changes to confer functional effects. In this context, either of the V3 loop changes could confer possible transitional R5X4 phenotypes, but when present together they completely abolished CCR5 usage and conferred the X4 phenotype. Our results show that the emergence of CXCR4-using strains is rare in this cohort of untreated individuals with advanced C-HIV infection. In the subject where X4 variants did emerge, alterations in the gp120 V3 loop were necessary but not sufficient to confer CXCR4 usage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cohort Studies
  • HIV Infections / metabolism*
  • HIV-1
  • Humans
  • Longitudinal Studies
  • Receptors, CCR5 / metabolism*
  • Receptors, CXCR4 / metabolism*

Substances

  • CCR5 protein, human
  • CXCR4 protein, human
  • Receptors, CCR5
  • Receptors, CXCR4

Grants and funding

This study was supported by grants from the Australian National Health and Medical Research Council to PRG and MJC (543133 & 1022066). MRJ was supported by grants from the Alfred Benzon and Aase and Ejner Danielsens foundations of Denmark. KC is supported by a University of Melbourne Postgraduate Research Scholarship. KB is supported by a Victorian International Research Scholarship. LRG is the recipient of an Australian National Health and Medical Research Council (NHMRC) Postdoctoral Training Fellowship. PAR is the Sir Zelman Cowen Senior Research Fellow (Sir Zelman Cowen Fellowship Fund, Burnet Institute). PRG was the recipient of an Australian NHMRC Level 2 Biomedical Career Development Award, and is presently supported by an Australian Research Council Future Fellowship (FT2). The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.